Cargando…

Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis

INTRODUCTION: Circulating tumor DNA (ctDNA) has provided a minimally invasive approach for the detection of genetic mutations in glioma. However, the diagnostic value of ctDNA in glioma remains unclear. This meta-analysis was designed to investigate the diagnostic value of ctDNA, compared with the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yin, Lin, Xiaohua, Kang, Dezhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437834/
https://www.ncbi.nlm.nih.gov/pubmed/32871983
http://dx.doi.org/10.1097/MD.0000000000021196
_version_ 1783572698440400896
author Kang, Yin
Lin, Xiaohua
Kang, Dezhi
author_facet Kang, Yin
Lin, Xiaohua
Kang, Dezhi
author_sort Kang, Yin
collection PubMed
description INTRODUCTION: Circulating tumor DNA (ctDNA) has provided a minimally invasive approach for the detection of genetic mutations in glioma. However, the diagnostic value of ctDNA in glioma remains unclear. This meta-analysis was designed to investigate the diagnostic value of ctDNA, compared with the current “criterion standard” tumor tissues. MATERIALS AND METHODS: The included studies were collected by searching PubMed, Web of Science, Cochrane Library, and Embase databases. All statistical analyses were performed using the STATA12.0 and Meta-DiSc1.4 software. RESULT: A total of 11 studies comprising 522 glioma patients met our inclusion criteria. The pooled sensitivity and specificity were 0.69 (95% confidence interval [CI] 0.66–0.73) and 0.98 (95% CI 0.96–0.99), respectively. The pooled diagnostic odds ratio was 23.27 (95% CI 13.69–39.53) and the area under the curve of the summary receiver operating characteristics curve was 0.90 (95% CI 0.89–0.92). CONCLUSIONS: ctDNA analysis is an effective method to detect the genetic mutation status in glioma patients with high specificity and relatively moderate sensitivity. The application of high-throughput technologies, the detection of patients with high-grade glioma, and sampling from cerebrospinal fluid could have higher diagnostic accuracy. The improvement of detection methods and more large-sample case–control studies are required in the future.
format Online
Article
Text
id pubmed-7437834
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74378342020-09-02 Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis Kang, Yin Lin, Xiaohua Kang, Dezhi Medicine (Baltimore) 5700 INTRODUCTION: Circulating tumor DNA (ctDNA) has provided a minimally invasive approach for the detection of genetic mutations in glioma. However, the diagnostic value of ctDNA in glioma remains unclear. This meta-analysis was designed to investigate the diagnostic value of ctDNA, compared with the current “criterion standard” tumor tissues. MATERIALS AND METHODS: The included studies were collected by searching PubMed, Web of Science, Cochrane Library, and Embase databases. All statistical analyses were performed using the STATA12.0 and Meta-DiSc1.4 software. RESULT: A total of 11 studies comprising 522 glioma patients met our inclusion criteria. The pooled sensitivity and specificity were 0.69 (95% confidence interval [CI] 0.66–0.73) and 0.98 (95% CI 0.96–0.99), respectively. The pooled diagnostic odds ratio was 23.27 (95% CI 13.69–39.53) and the area under the curve of the summary receiver operating characteristics curve was 0.90 (95% CI 0.89–0.92). CONCLUSIONS: ctDNA analysis is an effective method to detect the genetic mutation status in glioma patients with high specificity and relatively moderate sensitivity. The application of high-throughput technologies, the detection of patients with high-grade glioma, and sampling from cerebrospinal fluid could have higher diagnostic accuracy. The improvement of detection methods and more large-sample case–control studies are required in the future. Lippincott Williams & Wilkins 2020-08-14 /pmc/articles/PMC7437834/ /pubmed/32871983 http://dx.doi.org/10.1097/MD.0000000000021196 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Kang, Yin
Lin, Xiaohua
Kang, Dezhi
Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis
title Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis
title_full Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis
title_fullStr Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis
title_full_unstemmed Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis
title_short Diagnostic value of circulating tumor DNA in molecular characterization of glioma: A meta-analysis
title_sort diagnostic value of circulating tumor dna in molecular characterization of glioma: a meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437834/
https://www.ncbi.nlm.nih.gov/pubmed/32871983
http://dx.doi.org/10.1097/MD.0000000000021196
work_keys_str_mv AT kangyin diagnosticvalueofcirculatingtumordnainmolecularcharacterizationofgliomaametaanalysis
AT linxiaohua diagnosticvalueofcirculatingtumordnainmolecularcharacterizationofgliomaametaanalysis
AT kangdezhi diagnosticvalueofcirculatingtumordnainmolecularcharacterizationofgliomaametaanalysis